These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23668924)

  • 1. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
    Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG
    Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
    Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R
    BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
    Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
    Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
    Garnock-Jones KP
    Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
    Dohin E; Högl B; Ferini-Strambi L; Schollmayer E; Fichtner A; Bauer L; García-Borreguero D
    Expert Opin Pharmacother; 2013 Jan; 14(1):15-25. PubMed ID: 23256574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis-Ekbom disease).
    Elshoff JP; Hudson J; Picchietti DL; Ridel K; Walters AS; Doggett K; Moran K; Oortgiesen M; Ramirez F; Schollmayer E
    Sleep Med; 2017 Apr; 32():48-55. PubMed ID: 28366342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study.
    Stiasny-Kolster K; Kohnen R; Schollmayer E; Möller JC; Oertel WH;
    Mov Disord; 2004 Dec; 19(12):1432-8. PubMed ID: 15390055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal rotigotine in restless legs syndrome: impulse control disorders.
    Prescrire Int; 2014 Oct; 23(153):239. PubMed ID: 25964969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
    Bauer A; Cassel W; Benes H; Kesper K; Rye D; Sica D; Winkelman JW; Bauer L; Grieger F; Joeres L; Moran K; Schollmayer E; Whitesides J; Carney HC; Walters AS; Oertel W; Trenkwalder C;
    Neurology; 2016 May; 86(19):1785-93. PubMed ID: 27164714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study.
    Inoue Y; Shimizu T; Hirata K; Uchimura N; Ishigooka J; Oka Y; Ikeda J; Tomida T; Hattori N;
    Sleep Med; 2013 Nov; 14(11):1085-91. PubMed ID: 24055212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
    Oertel WH; Benes H; Garcia-Borreguero D; Högl B; Poewe W; Montagna P; Ferini-Strambi L; Sixel-Döring F; Trenkwalder C; Partinen M; Saletu B; Polo O; Fichtner A; Schollmayer E; Kohnen R; Cassel W; Penzel T; Stiasny-Kolster K
    Sleep Med; 2010 Oct; 11(9):848-56. PubMed ID: 20813583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
    Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
    Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.